The cell banking outsourcing market is projected to grow from USD 16.78 billion in 2025 to USD 42.31 billion by 2031, with a CAGR of 16.71%. Growth is driven by increasing demand for biologics, cell and gene therapies, and regenerative medicine. North America leads the market while Asia-Pacific emerges as a high-growth region. Biopharmaceutical companies are increasingly outsourcing cell banking operations to improve efficiency and reduce costs.

The plasmid DNA manufacturing market is projected to grow from USD 2.4 billion in 2025 to USD 10.8 billion by 2034, driven by rising demand for gene therapies, DNA vaccines, and CAR-T treatments. North America leads the market with 44.12% share, while Asia-Pacific emerges as a significant growth engine. Major companies are expanding GMP-compliant manufacturing capabilities to meet increasing demand from biopharmaceutical companies and CDMOs.

The AAV vector manufacturing market is projected to grow from USD 874 million in 2025 to USD 5.2 billion by 2034, driven by expanding gene therapy research, increasing regulatory approvals, and rising investments in biomanufacturing infrastructure. North America leads the market with 43% share, while Asia-Pacific emerges as a key growth engine. Key drivers include growing prevalence of genetic disorders, technological advancements in manufacturing, and expansion of outsourcing to CDMOs.

The drug development services market is projected to grow from $28.09 billion in 2025 to $50.26 billion by 2030 at a CAGR of 12.4%, driven by increased R&D investments, AI adoption, personalized medicine, and emerging market expansion. Key growth areas include preclinical research, regulatory optimization, and cloud-based data management, with precision medicine and genomics advancements playing pivotal roles.

ResearchAndMarkets.com is offering a two-day online training course (May 13-14, 2026) on implementing VICH Good Clinical Practice principles in veterinary clinical trials. The course aims to enhance trial efficiency, ensure regulatory compliance, and improve data quality for EU and USA acceptance. It covers protocol design, data management, monitoring, and quality assurance with expert instructors including Donna Taylor and Jenny Webster.

The global Pharmaceutical Microbiology QC Testing Market is projected to grow from USD 5.08 billion in 2025 to USD 17.65 billion by 2035, at a CAGR of 13.27%. Growth is driven by increased regulatory oversight, laboratory automation, antimicrobial resistance concerns, and adoption of advanced technologies like AI-enabled molecular platforms and MALDI-TOF mass spectrometry. North America leads with 39.12% market share, while Asia Pacific is expected to grow fastest at 14.33% CAGR.

Charles River Laboratories announced significant divestiture plans, selling its CDMO and Cell Solutions businesses to GI Partners, and certain European Discovery Services assets to IQVIA Holdings. The divestitures will reduce 2026 revenue by over $200 million but are expected to improve adjusted operating margins by at least 100 basis points and add approximately 10 cents to adjusted EPS. The company raised its fiscal 2026 adjusted earnings guidance to $10.80-$11.30.

The global Adeno Associated Virus (AAV) vector manufacturing market is projected to grow from USD 2.84 billion in 2025 to USD 9.87 billion by 2035, at a CAGR of 13.4%. Growth is driven by increased clinical trials, regulatory approvals of AAV-based gene therapies, technological innovations in manufacturing processes, and rising demand from pharmaceutical companies and CDMOs. North America leads the market while Asia Pacific shows the fastest growth rate.

The global lead optimization services in drug discovery market is projected to grow from USD 4.26 billion in 2024 to USD 10.26 billion by 2034, driven by rising R&D activities, technological advancements, and increasing outsourcing trends in pharmaceutical research.

The global innovative drug CRO market is projected to grow from USD 59.63 billion in 2026 to USD 96.06 billion by 2035, with a 5.44% CAGR, driven by increasing R&D costs, clinical trial complexities, and technological advancements.

Charles River Laboratories reported Q3 2025 earnings beating expectations, with revenue of $1.01 billion, but lowered full-year guidance and announced strategic asset sales, causing stock to decline.

The global cell-based assays market is projected to grow from USD 17.11 billion in 2023 to USD 35.34 billion by 2032, driven by increasing demand in drug discovery, toxicity testing, and advanced biotechnology research.